Thyroid hormone receptor-β is associated with coronary angiogenesis during pathological cardiac hypertrophy

Endocrinology

Volumn 150, Issue 4, 2009, Pages 2008-2015

  Makino, Ayako ^a   Suarez, Jorge ^a   Wang, Hong ^a   Belke, Darrell D ^a   Scott, Brian T ^a   Dillmann, Wolfgang H ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; MESSENGER RNA; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; HEART DEVELOPMENT; HEART FUNCTION; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CARDIOMEGALY; CORONARY VESSELS; ENDOTHELIAL CELLS; HEART VENTRICLES; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; THYROID HORMONE RECEPTORS BETA; TRIIODOTHYRONINE;

EID: 63849163509     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0634     Document Type: Article

References (46)

1. Yla-Herttuala S, Martin JF 2000 Cardiovascular gene therapy. Lancet 355: 213-222
2. Tamirisa KP, Mukherjee D 2002 Gene therapy in cardiovascular diseases. Curr Gene Ther 2:427-435
3. Mukherjee D 2004 Current clinical perspectives on myocardial angiogenesis. Mol Cell Biochem 264:157-167
4. Klein I, Ojamaa K 2001 Thyroid hormone and the cardiovascular system. N Engl J Med 344:501-509
5. Motomura K, Brent GA 1998 Mechanisms of thyroid hormone action. Implications for the clinical manifestation of thyrotoxicosis. Endocrinol Metab Clin North Am 27:1-23
6. Hamilton MA, Stevenson LW, Fonarow GC, Steimle A, Goldhaber JI, Child JS, Chopra IJ, Moriguchi JD, Hage A 1998 Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 81:443-447
7. Morkin E, Pennock GD, Spooner PH, Bahl JJ, Goldman S 2002 Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 12:527-533
8. Degens H, Gilde AJ, Lindhout M, Willemsen PH, Van Der Vusse GJ, Van Bilsen M 2003 Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am J Physiol Heart Circ Physiol 284:H108 -H115
9. Ladenson PW 1990 Recognition and management of cardiovascular disease related to thyroid dysfunction. Am J Med 88:638-641
10. Harvey CB, Williams GR 2002 Mechanism of thyroid hormone action. Thyroid 12:441-446
11. Freedman LP 1992 Anatomy of the steroid receptor zinc finger region. Endocr Rev 13:129-145
12. Katz D, Lazar MA 1993 Dominant negative activity of an endogenous thyroid hormone receptor variant (α2) is due to competition for binding sites on target genes. J Biol Chem 268:20904-20910
13. Kinugawa K, Minobe WA, Wood WM, Ridgway EC, Baxter JD, Ribeiro RC, Tawadrous MF, Lowes BA, Long CS, Bristow MR 2001 Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 103:1089-1094
14. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, Bristow MR, Long CS, Simpson PC 2001 Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89:591-598
15. Belke DD, Gloss B, Swanson EA, Dillmann WH 2007 Adeno-associated virus- mediated expression of thyroid hormone receptor isoforms-α1 and -β1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology 148:2870-2877
16. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen NH, Scanlan TS, Moskowitz MA, Cheng SY, Liao JK 2006 Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 103:14104-14109
17. Diekman MJ, Zandieh Doulabi B, Platvoet-Ter Schiphorst M, Fliers E, Bakker O, Wiersinga WM 2001 The biological relevance of thyroid hormone receptors in immortalized human umbilical vein endothelial cells. J Endocrinol 168: 427-433
18. Wang X, Zheng W, Christensen LP, Tomanek RJ 2003 DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am JPhysiol Heart Circ Physiol 284:H613-H618
19. Heron MI, Kolar F, Papousek F, Rakusan K 1997 Early and late effect of neonatal hypoand hyperthyroidism on coronary capillary geometry and long- term heart function in rat. Cardiovasc Res 33:230 -240
20. Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ 2005 The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46:356-360
21. Tomanek RJ, Connell PM, Butters CA, Torry RJ 1995 Compensated coronary microvascular growth in senescent rats with thyroxine-induced cardiac hypertrophy. Am JPhysiol 268:H419-H245
22. Anjos-Ramos L, Carneiro-Ramos MS, Diniz GP, Martins-Silva J, Barreto- Chaves ML 2006 Early cardiac hypertrophy induced by thyroxine is accompanied by anincrease in VEGF-Aexpression but not by an increase in capillary density. Virchows Arch 448:472-479
23. Suarez J, Gloss B, Belke DD, Hu Y, Scott B, Dieterle T, Kim YK, Valencik ML, McDonald JA, Dillmann WH 2004 Doxycycline inducible expression of SERCA2aimprovescalciumhandlingandreverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 287:H2164-H2172
24. Wikstrom L, Johansson C, Salto C, Barlow C, Campos Barros A, Baas F, Forrest D, Thorén P, Vennström B 1998 Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor α1. EMBO J 17: 455-461
25. Gauthier K, Chassande O, Plateroti M, Roux JP, Legrand C, Pain B, Rousset B, Weiss R, Trouillas J, Samarut J 1999 Different functions for the thyroid hormone receptors TRα and TRβ in the control of thyroid hormone production and post-natal development. EMBO J 18:623-631
26. Sohal DS, Nghiem M, Crackower MA, MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD 2001 Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-in- ducible Cre protein. Circ Res 89:20 -25
27. FlamantF,Samarut J 2003 Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab 14:85-90
28. Makino A, Platoshyn O, Suarez J, Yuan JX, Dillmann WH 2008 Downregulation of connexin40 is associated with coronary endothelial cell dysfunction in streptozotocin-induced diabetic mice. Am J Physiol Cell Physiol 295:C221-C230
29. Williams JL, Weichert A, Zakrzewicz A, Da Silva-Azevedo L, Pries AR, Baum O, Egginton S 2006 Differential gene and protein expression in abluminal sprouting and intraluminal splitting forms of angiogenesis. Clin Sci (Lond) 110:587-595
30. Breisch EA, White FC, Nimmo LE, Bloor CM 1986 Cardiac vasculature and flow during pressure-overload hypertrophy. Am J Physiol 251:H1031-H1037
31. Breisch EA, White FC, Bloor CM 1984 Myocardial characteristics of pressure overload hypertrophy. A structural and functional study. Lab Invest 51:333-342
32. Mueller TM, Marcus ML, Kerber RE, Young JA, Barnes RW, Abboud FM 1978 Effect of renal hypertension and left ventricular hypertrophy on the coronary circulation in dogs. Circ Res 42:543-549
33. Villicev CM, Freitas FR, Aoki MS, Taffarel C, Scanlan TS, Moriscot AS, Ribeiro MO, Bianco AC, Gouveia CH 2007 Thyroid hormone receptor β-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol 193:21-29
34. Berne RM 1964 Regulation of coronary blood flow. Physiol Rev 44:1-29
35. Tomanek RJ, Palmer PJ, Peiffer GL, Schreiber KL, Eastham CL, Marcus ML 1986 Morphometry of canine coronary arteries, arterioles, and capillaries during hypertension and left ventricular hypertrophy. Circ Res 58:38 -46
36. Flanagan MF, Fujii AM, Colan SD, Flanagan RG, Lock JE 1991 Myocardial angiogenesis and coronary perfusion in left ventricular pressure-overload hypertrophy in the young lamb. Evidence for inhibition with chronic protamine administration. Circ Res 68:1458-1470
37. Jiang Y, Reynolds C, Xiao C, Feng W, Zhou Z, Rodriguez W, Tyagi SC, Eaton JW, Saari JT, Kang YJ 2007 Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 204:657-666
38. Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S, Molkentin JD, Zou Y, Komuro I 2007 p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446: 444-448
39. Ercan-Fang S, Schwartz HL, Oppenheimer JH 1996 Isoform-specific 3,5,3'- triiodothyronine receptor binding capacity and messenger ribonucleic acid content in rat adenohypophysis: effect of thyroidal state and comparison with extrapituitary tissues. Endocrinology 137:3228 -3233
40. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K 1998 Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98: 2108-2116
41. Walsh DA 2007 Pathophysiological mechanisms of angiogenesis. Adv Clin Chem 44:187-221
42. Dedecjus M, Kolomecki K, Brzezinski J, Adamczewski Z, Tazbir J, Lewinski A2007 Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma. Endocr J 54:63-69
43. Monden T, Nakajima Y, Hashida T, Ishii S, Tomaru T, Shibusawa N, Hashimoto K, Satoh T, Yamada M, Mori M, Kasai K 2006 Expression of thyroid hormone receptor isoforms down-regulated by thyroid hormone in human medulloblastoma cells. Endocr J 53:181-187
44. Opitz R, Lutz I, Nguyen NH, Scanlan TS, Kloas W 2006 Analysis of thyroid hormone receptor betaA mRNA expression in Xenopus laevis tadpoles as a means to detect agonism and antagonism of thyroid hormone action. Toxicol Appl Pharmacol 212:1-13
45. Shi YB, Ritchie JW, Taylor PM 2002 Complex regulation of thyroid hormone action: multiple opportunities for pharmacological intervention. Pharmacol Ther 94:235-251
46. Hayashi Y, Mangoura D, Refetoff S 1996 A mouse model of resistance to thyroid hormone produced by somatic gene transfer of a mutant thyroid hormone receptor. Mol Endocrinol 10:100-106